drugset / Trial / NCT03489616

Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients

NCT03489616

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether chemotherapy combination with local radiotherapy and rhGM-CSF is safe, effective in the treatment of oligometastatic stage IV NSCLC patients.

Timeline

Start
2018-01-15
Primary completion
2019-07-01
Completion
2019-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule
Subject Gemcitabine Small molecule
Subject Pemetrexed Small molecule 500 mg/m2
Subject rhGM-CSF Protein / enzyme biologic 200 ug/m2 Subcutaneous